687 related articles for article (PubMed ID: 28518151)
21. Lower phosphorylation of p38 MAPK blocks the oxidative stress-induced senescence in myeloid leukemic CD34(+)CD38 (-) cells.
Xiao Y; Zou P; Wang J; Song H; Zou J; Liu L
J Huazhong Univ Sci Technolog Med Sci; 2012 Jun; 32(3):328-333. PubMed ID: 22684553
[TBL] [Abstract][Full Text] [Related]
22. Immunoprofiling of leukemic stem cells CD34+/CD38-/CD123+ delineate FLT3/ITD-positive clones.
Al-Mawali A; Gillis D; Lewis I
J Hematol Oncol; 2016 Jul; 9(1):61. PubMed ID: 27465508
[TBL] [Abstract][Full Text] [Related]
23. The Hsp32 inhibitors SMA-ZnPP and PEG-ZnPP exert major growth-inhibitory effects on D34+/CD38+ and CD34+/CD38- AML progenitor cells.
Herrmann H; Kneidinger M; Cerny-Reiterer S; Rülicke T; Willmann M; Gleixner KV; Blatt K; Hörmann G; Peter B; Samorapoompichit P; Pickl W; Bharate GY; Mayerhofer M; Sperr WR; Maeda H; Valent P
Curr Cancer Drug Targets; 2012 Jan; 12(1):51-63. PubMed ID: 22165967
[TBL] [Abstract][Full Text] [Related]
24. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
25. Phenotyping and Target Expression Profiling of CD34
Blatt K; Menzl I; Eisenwort G; Cerny-Reiterer S; Herrmann H; Herndlhofer S; Stefanzl G; Sadovnik I; Berger D; Keller A; Hauswirth A; Hoermann G; Willmann M; Rülicke T; Sill H; Sperr WR; Mannhalter C; Melo JV; Jäger U; Sexl V; Valent P
Neoplasia; 2018 Jun; 20(6):632-642. PubMed ID: 29772458
[TBL] [Abstract][Full Text] [Related]
26. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors.
Venton G; Pérez-Alea M; Baier C; Fournet G; Quash G; Labiad Y; Martin G; Sanderson F; Poullin P; Suchon P; Farnault L; Nguyen C; Brunet C; Ceylan I; Costello RT
Blood Cancer J; 2016 Sep; 6(9):e469. PubMed ID: 27611922
[TBL] [Abstract][Full Text] [Related]
27. The Multi-kinase Inhibitor Debio 0617B Reduces Maintenance and Self-renewal of Primary Human AML CD34
Murone M; Radpour R; Attinger A; Chessex AV; Huguenin AL; Schürch CM; Banz Y; Sengupta S; Aguet M; Rigotti S; Bachhav Y; Massière F; Ramachandra M; McAllister A; Riether C
Mol Cancer Ther; 2017 Aug; 16(8):1497-1510. PubMed ID: 28468777
[TBL] [Abstract][Full Text] [Related]
28. Preferential eradication of acute myelogenous leukemia stem cells by fenretinide.
Zhang H; Mi JQ; Fang H; Wang Z; Wang C; Wu L; Zhang B; Minden M; Yang WT; Wang HW; Li JM; Xi XD; Chen SJ; Zhang J; Chen Z; Wang KK
Proc Natl Acad Sci U S A; 2013 Apr; 110(14):5606-11. PubMed ID: 23513221
[TBL] [Abstract][Full Text] [Related]
29. MUC1 is a potential target for the treatment of acute myeloid leukemia stem cells.
Stroopinsky D; Rosenblatt J; Ito K; Mills H; Yin L; Rajabi H; Vasir B; Kufe T; Luptakova K; Arnason J; Nardella C; Levine JD; Joyce RM; Galinsky I; Reiter Y; Stone RM; Pandolfi PP; Kufe D; Avigan D
Cancer Res; 2013 Sep; 73(17):5569-79. PubMed ID: 23867470
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
Zhou B; Qin Y; Zhou J; Ruan J; Xiong F; Dong J; Huang X; Yu Z; Gao S
J Cell Mol Med; 2021 Mar; 25(6):3124-3135. PubMed ID: 33599085
[TBL] [Abstract][Full Text] [Related]
31. MTH1 Inhibitor TH1579 Induces Oxidative DNA Damage and Mitotic Arrest in Acute Myeloid Leukemia.
Sanjiv K; Calderón-Montaño JM; Pham TM; Erkers T; Tsuber V; Almlöf I; Höglund A; Heshmati Y; Seashore-Ludlow B; Nagesh Danda A; Gad H; Wiita E; Göktürk C; Rasti A; Friedrich S; Centio A; Estruch M; Våtsveen TK; Struyf N; Visnes T; Scobie M; Koolmeister T; Henriksson M; Wallner O; Sandvall T; Lehmann S; Theilgaard-Mönch K; Garnett MJ; Östling P; Walfridsson J; Helleday T; Warpman Berglund U
Cancer Res; 2021 Nov; 81(22):5733-5744. PubMed ID: 34593524
[TBL] [Abstract][Full Text] [Related]
32. Leukemia-initiating cells from some acute myeloid leukemia patients with mutated nucleophosmin reside in the CD34(-) fraction.
Taussig DC; Vargaftig J; Miraki-Moud F; Griessinger E; Sharrock K; Luke T; Lillington D; Oakervee H; Cavenagh J; Agrawal SG; Lister TA; Gribben JG; Bonnet D
Blood; 2010 Mar; 115(10):1976-84. PubMed ID: 20053758
[TBL] [Abstract][Full Text] [Related]
33. Antineoplastic mechanisms of niclosamide in acute myelogenous leukemia stem cells: inactivation of the NF-kappaB pathway and generation of reactive oxygen species.
Jin Y; Lu Z; Ding K; Li J; Du X; Chen C; Sun X; Wu Y; Zhou J; Pan J
Cancer Res; 2010 Mar; 70(6):2516-27. PubMed ID: 20215516
[TBL] [Abstract][Full Text] [Related]
34. Long term maintenance of myeloid leukemic stem cells cultured with unrelated human mesenchymal stromal cells.
Ito S; Barrett AJ; Dutra A; Pak E; Miner S; Keyvanfar K; Hensel NF; Rezvani K; Muranski P; Liu P; Larochelle A; Melenhorst JJ
Stem Cell Res; 2015 Jan; 14(1):95-104. PubMed ID: 25535865
[TBL] [Abstract][Full Text] [Related]
35. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells.
Guzman ML; Rossi RM; Karnischky L; Li X; Peterson DR; Howard DS; Jordan CT
Blood; 2005 Jun; 105(11):4163-9. PubMed ID: 15687234
[TBL] [
